Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Hypertension. 2015 Aug;66(2):301–308. doi: 10.1161/HYPERTENSIONAHA.115.05603

Table 3.

Linear and Logistic Regression Analysis of Cardiometabolic Outcomes Associated with Urinary Phthalate Metabolites.

Blood Pressure
Outcome (n=1329)
Z-score Increment,
Systolic Blood
Pressure
Z-score Increment,
Diastolic Blood
Pressure
Odds Ratio, Blood Pressure
≥90th Percentile
LMW Metabolites +0.02 (−0.05, +0.10) +0.04 (−0.16, +0.24) 1.12 (0.79, 1.59)
HMW Metabolites +0.12 (+0.03, +0.21) +0.06 (−0.03, +0.16) 1.30 (0.78, 2.17)
DEHP Metabolites +0.10 (+0.03, +0.18)* +0.09 (+0.04, +0.17)* 1.31 (0.90, 1.91)
DIDP Metabolites +0.11 (+0.04, +0.17) +0.03 (−0.04, +0.10) 0.99 (0.66, 1.48)
DINP Metabolites +0.11 (+0.03, +0.19) +0.02 (−0.09, +0.13) 1.19 (0.72, 1.98)
Triglyceride Outcome (n=350) Odds Ratio, Elevated Triglycerides Increment, Triglycerides
LMW Metabolites 0.83 (0.62, 1.12) −0.04 (−0.10, +0.007)
HMW Metabolites 1.07 (0.81, 1.42) −0.008 (−0.06, +0.04)
DEHP Metabolites 0.91 (0.69, 1.19) −0.02 (−0.07, +0.03)
DIDP Metabolites 1.01 (0.76, 1.36) −0.01 (−0.06, +0.04)
DINP Metabolites 1.19 (0.97, 1.47) +0.005 (−0.03, +0.04)
HDL Outcome (n=1186) Odds Ratio, Low HDL Increment, HDL
LMW Metabolites 1.17 (0.81, 1.71) +0.46 (−0.57, +1.50)
HMW Metabolites 0.93 (0.66, 1.32) +0.98 (−0.25, +2.20)
DEHP Metabolites 0.89 (0.58, 1.36) +1.20 (−0.17, +2.58)
DIDP Metabolites 0.97 (0.77, 1.23) −0.11 (−1.56, +1.33)
DINP Metabolites 0.89 (0.74, 1.05) +0.47 (−0.46, +1.40)

Increases are per log unit in urinary LMW/HMW/DEHP/DINP/DIDP metabolite concentration. See methods for calculation.

Models control for gender, caloric intake, physical activity, poverty-income ratio, serum cotinine, urinary creatinine, BMI category, race/ethnicity and age categories.

Results using weighted modeling are presented here for blood pressure and HDL outcomes; trygliceride outcome results are presented unweighted (see methods).

*

p <0.05

p <0.01

p<0.001